focus -WSS

focus

author：knowledge 2025-09-27 16:46:37 - browse：45

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： The surgeon had a dilemma only a Nazi medical text could resolve

WSS

FDA clears AI tool for detecting skin cancer

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Prior authorization will have to move faster under new Biden rule

Some medical students still think black patients feel less pain

New brain studies show LSD's effects on the brain in full color

Copay coupons to count toward deductibles, after Biden court move

knowledge

focus

knowledge

Tori Bowie and the unacceptable rates of Black maternal death

Some medical students still think black patients feel less pain

Bright Health sells Medicare Advantage business to Molina

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

After affirmative action ruling, medical educators look to 'holistic review'

Dewpoint Therapeutics lays off staff after losing partnerships

Duchenne breakthrough therapy leaves behind pioneering families

New brain studies show LSD's effects on the brain in full color

Moonlake's readout produced a cash windfall. Risks remain

NIH director takes cautious approach to Biden drug pricing priority

knowledge

Unmasking the 'centricity' illusion in clinical trials

Beyond aggravation: Constipation is an American epidemic

Achieving telehealth equity for people with hearing loss

The surgeon had a dilemma only a Nazi medical text could resolve

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Beyond aggravation: Constipation is an American epidemic

leisure time

knowledge

leisure time

focus